8-K: Avenue Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Avenue Therapeutics reported its third quarter 2024 financial results and provided an update on its clinical programs, including the anticipated topline data for AJ201.

Summary

• Avenue Therapeutics announced its financial results for the third quarter ended September 30, 2024, along with updates on its clinical programs.
• The company's cash and cash equivalents stood at $2.6 million as of September 30, 2024, a decrease from $4.9 million at the end of the previous quarter.
• Research and development expenses for the third quarter were $2.3 million, up from $0.9 million in the same period last year.
• General and administrative expenses decreased to $0.8 million in the third quarter of 2024, compared to $1.2 million in the third quarter of 2023.
• The net loss attributable to common stockholders for the third quarter was $3.1 million, or $1.92 per share, compared to a net income of $0.5 million, or $4.86 per share, for the same period in 2023.
• Topline data from the Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy is expected around year-end 2024.
• Avenue plans to initiate a Phase 2a clinical trial of BAER-101 for focal epilepsy, subject to additional financing.
• The company has reached an agreement with the FDA on the safety study protocol for the Phase 3 study of IV tramadol for post-operative pain, with study initiation dependent on additional financing or a partnership.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the increased net loss, decreased cash position, and the need for additional funding. However, there is some positive sentiment due to the progress in clinical trials and the agreement with the FDA.

Positives

• The company has completed the last patient visit in the Phase 1b/2a clinical trial of AJ201.
• Avenue has reached an agreement with the FDA on the safety study protocol for the Phase 3 study of IV tramadol.
• Preclinical models have shown BAER-101 to fully suppress seizure activity with a fast onset and stable effect.
• General and administrative expenses decreased in the third quarter of 2024 compared to the same period in 2023.

Negatives

• The company's cash position decreased to $2.6 million, down from $4.9 million at the end of the previous quarter.
• Avenue reported a net loss of $3.1 million for the third quarter of 2024, a significant decrease from the net income of $0.5 million in the same period of 2023.
• The initiation of Phase 2a clinical trial of BAER-101 and Phase 3 study of IV tramadol are contingent on additional financing or partnerships.
• The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future.

Risks

• The company's success is dependent on receiving regulatory approval and successfully commercializing its product candidates.
• There is a risk of serious adverse side effects during the development of product candidates.
• The company needs substantial additional funding, which may not be available on acceptable terms.
• Avenue relies on third parties for several aspects of its operations.
• There is a risk that the company may not receive regulatory approval for its product candidates.
• The company faces competition from other pharmaceutical companies.
• There is a risk that the government or third-party payors may not provide adequate coverage for the company's products.
• The company is exposed to potential product liability claims.
• The company may not be able to maintain sufficient patent protection for its technology and products.
• Fortress Biotech, Inc. controls a majority of the voting power of the company's outstanding capital stock.

Future Outlook

The company anticipates topline data from the Phase 1b/2a clinical trial of AJ201 around year-end 2024, plans to initiate a Phase 2a clinical trial of BAER-101 subject to additional financing, and aims to initiate the Phase 3 safety study of IV tramadol pending additional financing or a partnership. The company believes the IV tramadol study can be completed and submitted to the FDA within 12 months of initiation.

Management Comments

• Alexandra MacLean, M.D., Chief Executive Officer of Avenue, stated that the company has generated considerable momentum this past quarter in advancing its pipeline of innovative treatments for neurologic diseases.
• She also mentioned that AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet medical need in Kennedys Disease.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies focused on developing treatments for neurologic diseases. The progress of AJ201, BAER-101, and IV tramadol is being closely watched by investors and competitors in the space. The company's financial position and need for additional funding are also important factors in the current market environment.

Comparison to Industry Standards

• Avenue's R&D spending of $2.3 million for the quarter is relatively low compared to larger pharmaceutical companies, but is typical for a company of its size and stage of development.
• The net loss of $3.1 million is not unusual for a clinical-stage biotech company, as these companies often incur significant losses while developing their products.
• The company's cash position of $2.6 million is relatively low and highlights the need for additional funding to continue operations and clinical trials.
• Companies like Biogen, Ionis Pharmaceuticals, and Sarepta Therapeutics are also developing treatments for neurological diseases, and their progress and financial results are often used as benchmarks for comparison.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the need for additional financing.
• Employees may be affected by the company's financial situation and the potential for delays in clinical programs.
• Patients may benefit from the development of new treatments for neurologic diseases.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company anticipates topline data from the Phase 1b/2a clinical trial of AJ201 around year-end 2024.
• Avenue plans to initiate a Phase 2a clinical trial of BAER-101, subject to additional financing.
• The company aims to initiate the Phase 3 safety study of IV tramadol pending additional financing or a partnership.

Key Dates

Keywords

Avenue Therapeutics, ATXI, AJ201, BAER-101, IV Tramadol, Spinal and Bulbar Muscular Atrophy, Focal Epilepsy, Post-operative Pain, Clinical Trial, Phase 3, Phase 2a, FDA, Neurologic Diseases, Pharmaceutical, Biotech